Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease
{{output}}
Background/aims: Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn's disease (CD). Refractory disease is common, a com... ...
